ArcherDx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired - II | Acquired

Total Raised




About ArcherDx

ArcherDX offers a bioinformatics platform for targeted sequencing applications featuring proprietary Anchored Multiplexed PCR (AMP) chemistry in a lyophilized format.On June 22nd, 2020, ArcherDx was acquired by Invitae at a valuation between $325 and $1400M.

ArcherDx Headquarter Location

2477 55th Street Suite 202

Boulder, Colorado, 80301,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ArcherDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ArcherDx is included in 6 Expert Collections, including Cancer.



105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Medical Devices

8,520 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

12,801 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx


Health IT

7,900 items

ArcherDx Patents

ArcherDx has filed 18 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Clusters of differentiation, Immune system, Immunology, DNA


Application Date


Grant Date



Related Topics

Molecular biology, Clusters of differentiation, Immune system, Immunology, DNA



Latest ArcherDx News

06:30 ET Global Genetic Testing Markets Report 2022: Direct to Consumer (DTC) Begins to Break Out

Jan 17, 2022

News provided by Share this article Share this article This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions. Is genomic cancer testing bouncing back? What has happened to Direct to Consumer testing? Will all newborns receive Whole Genomic Sequencing at birth? The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life, and new problems for the industry. Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. Genetic Testing Recent Developments Natera Launches Tumor Genomic Profiling Assay 23andMe To Go Public Ancestry Quits Health Offering Aetna Coverage for NIPT to Include All Pregnancies Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing Tumor, Germline Testing of Cancer Patients Can Give Discordant Results Invitae Completes Acquisition of ArcherDx Prenetics Receives $15M Investment Preconception Carrier Screening Trial Begins in Australia Genetic Testing Clinical Use Just Beginning Fulgent Genetics Q1 Revenues Jump 44 Percent Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic, Hematologic Disorders Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests Invitae Acquires Three Companies: YouScript, Genelex, Diploid PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients Phosphorus Offers DNA Testing to Assess Disease Risk Arivale Shuts Down Personalized Wellness Business ArcherDX Acquires Baby Genes

  • When was ArcherDx founded?

    ArcherDx was founded in 2013.

  • Where is ArcherDx's headquarters?

    ArcherDx's headquarters is located at 2477 55th Street, Boulder.

  • What is ArcherDx's latest funding round?

    ArcherDx's latest funding round is Acquired - II.

  • How much did ArcherDx raise?

    ArcherDx raised a total of $150M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.